Registered title, quoted from ClinicalTrials.gov
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Hunan Cancer Hospital; 2 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06840704, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically confirmed diagnosis of lung cancer, including non-small cell lung cancer and small cell lung cancer.
Inclusion criterion 3
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
Inclusion criterion 7
Known history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).
Exclusion criterion 10
Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06840704, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- The subject voluntarily participates in this clinical study, understands the study procedures, and is able to provide written informed consent.
- Age ≥ 18 years.
- Pathologically confirmed diagnosis of lung cancer, including non-small cell lung cancer and small cell lung cancer.
- Indication for thoracic radiotherapy, with the esophagus within 1 cm of the PTV.
- Prescription dose for the PTV: 60-70 Gy once daily (2 Gy/Fx), 45 Gy twice daily (1.5 Gy/Fx, with intervals exceeding 6 hours), or 45 Gy once daily (3 Gy/Fx).
- Ability to orally intake food normally.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- The volume of both lungs receiving more than 20 Gy (V20) should not exceed 30% of the total lung volume.
- Expected survival of more than 3 months.
- Laboratory test results during the screening period:
Complete blood count: ANC ≥ 1.5 × 10\^9/L; PLT ≥ 80 × 10\^9/L; Hb ≥ 90 g/L. Blood biochemistry: TBIL ≤ 1.5 × ULN; ALT and AST ≤ 2 × ULN; BUN and Cr ≤ 1.5 × ULN, with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula).
- Female subjects of childbearing potential, male subjects, and partners of male subjects agree to use reliable contraceptive methods during the study period (such as abstinence, sterilization, oral contraceptives, or other contraceptive measures).
Exclusion Criteria:
- Previous history of thoracic radiotherapy.
- Suspected or confirmed tumor invasion of the esophagus.
- Patients with other primary tumors.
- History of esophageal cancer, gastric cancer, or prior esophageal surgery.
- Concurrent active reflux esophagitis.
- Current regular use of immunonutrition (e.g., Oral Impact®).
- Patients with severe cardiovascular or cerebrovascular diseases, or comorbidities such as liver or kidney diseases.
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- Concurrent active autoimmune diseases requiring treatment.
- Known history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).
- Any medical (e.g., pulmonary, metabolic, endocrine, or neurological diseases, congenital disorders, etc.), psychiatric, or social condition that, in the investigator's judgment, may interfere with the subject's rights, safety, health, or ability to provide informed consent, cooperate and participate in the study, or interfere with the evaluation of the study drug, interpretation of patient safety, or study results.
Quoted from ClinicalTrials.gov, NCT06840704, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06840704, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.